title: High prevalence of fluoroquinolone-resistant group B streptococci among clinical isolates in China and predominance of sequence type 19 with serotype III.
abstract: A total of 146 group B streptococcus isolates from 8 cities across China belonged to four serotypes. Serotype Ia was more common in children. A high prevalence of resistance was observed for levofloxacin (37.7%), erythromycin (71.2%), clindamycin, (53.4%), and tetracycline (81.5%). The levofloxacin and clindamycin resistances among the 4 serotypes differed significantly. Eighty percent of fluoroquinolone-resistant isolates belonged to the sequence type 19 (ST19)/serotype III clone, with GyrA-ParC-ParE triple substitutions. This clone carried the erm(B), mef(E), and tet(M) genes.
authors.affiliation: Department of Clinical Laboratory, Peking University People's Hospital, Beijing, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Wang
authors.forename: Chunjiang
authors.initials: C
authors.lastname: Zhao
authors.forename: Wenqiang
authors.initials: W
authors.lastname: He
authors.forename: Feifei
authors.initials: F
authors.lastname: Zhang
authors.forename: Liyan
authors.initials: L
authors.lastname: Zhang
authors.forename: Bin
authors.initials: B
authors.lastname: Cao
authors.forename: Ziyong
authors.initials: Z
authors.lastname: Sun
authors.forename: Yingchun
authors.initials: Y
authors.lastname: Xu
authors.forename: Qing
authors.initials: Q
authors.lastname: Yang
authors.forename: Yaning
authors.initials: Y
authors.lastname: Mei
authors.forename: Bijie
authors.initials: B
authors.lastname: Hu
authors.forename: Yunzhuo
authors.initials: Y
authors.lastname: Chu
authors.forename: Kang
authors.initials: K
authors.lastname: Liao
authors.forename: Yunsong
authors.initials: Y
authors.lastname: Yu
authors.forename: Zhidong
authors.initials: Z
authors.lastname: Hu
authors.forename: Yuxing
authors.initials: Y
authors.lastname: Ni
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002681:China / Q000453:epidemiology; D002981:Clindamycin / Q000494:pharmacology / Q000627:therapeutic use*; D027081:DNA Gyrase / Q000235:genetics; D027101:DNA Topoisomerase IV / Q000235:genetics; D024881:Drug Resistance, Bacterial / Q000187:drug effects; D004917:Erythromycin / Q000494:pharmacology / Q000627:therapeutic use*; D005798:Genes, Bacterial; D006801:Humans; D064704:Levofloxacin; D008875:Middle Aged; D009154:Mutation; D015242:Ofloxacin / Q000494:pharmacology / Q000627:therapeutic use*; D015995:Prevalence; D012703:Serotyping; D013290:Streptococcal Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D013292:Streptococcus agalactiae / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D013752:Tetracycline / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D002981:Clindamycin; D004917:Erythromycin; D064704:Levofloxacin; D015242:Ofloxacin; D027101:DNA Topoisomerase IV; D027081:DNA Gyrase; D013752:Tetracycline